TY - JOUR AU - Leng, Yun AU - Qiu, Lugui AU - Hou, Jian AU - Zhao, Yaozhong AU - Zhang, Xuejun AU - Yang, Shifang AU - Xi, Hao AU - Huang, Zhongxia AU - Pan, Ling AU - Chen, Wenming PY - 2016 DA - 2016/09/08 TI - Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma JO - Chinese Journal of Cancer SP - 86 VL - 35 IS - 1 AB - Despite the recent development of new therapies, multiple myeloma (MM) remains an incurable disease. Thus, new, effective treatments are urgently needed, particularly for relapsed or refractory MM (RRMM). In an earlier phase I study, a novel form of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that is currently in clinical development for the treatment of hematologic malignancies, i.e., circularly permuted TRAIL (CPT), was well tolerated at a dose of 2.5 mg/kg per day and showed promising preliminary activity in patients with RRMM. This phase II, open-label, multicenter study further investigated the efficacy and safety of 2.5-mg/kg per day CPT as single-agent therapy for patients with RRMM. SN - 1944-446X UR - https://doi.org/10.1186/s40880-016-0140-0 DO - 10.1186/s40880-016-0140-0 ID - Leng2016 ER -